Clinical Trial

Effect of Dapagliflozin on Interleukin 10 in Sepsis

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to learn about the long-term effects of dapagliflozin as anti-inflammatory agents to improve organ dysfunction and decrease mortality on patients of both genders ageing 18 years or above with sepsis. 1ry Outcome: The anti-inflammatory effect of dapagliflozin in patients with sepsis evaluated by: Effect on inflammatory markers (IL-10). 2ry Outcomes: 1. Severity of sepsis evaluated by the SOFA score. 2. Prognostic value of HDL compared to IL-10 for multi organ failure and death in septic patients and their correlation to the severity of sepsis. 3. ICU mortality \&hospital length stay.
Trial Details
NCT Number NCT07206160
Lead Sponsor Minia University
Conditions Sepsis
Enrollment 64 participants
Start Date 2025-10-01
Primary Completion 2026-10-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-03